Advertisement

Journey Medical Corporation DERM

Set alert

Price alert · DERM

All alert types
5.17 USD -0.24 -4.44%

At close · Oct 30

5.20 +0.03 +0.58%

After hours · Oct 30, 4:00 PM ET

Bid
5.16 × 2
Ask
5.20 × 2
5.10 Day range 5.36
4.39 52-week range 9.26
YTD
-32.94%
1 year
-37.79%
Open
5.36
Prev close
5.41
Mkt cap
145.92M
Vol
235.06K
Avg vol
197.05K
EPS
-0.22
P/E
0.00
Div yield
0.00%
More statistics
Low
5.10
High
5.36
Forward P/E
-75.83
Beta
0.00
Short ratio
0.55
Inst. own
24.86%
Dividend
0.00
Ex-div date
Earnings
Aug 12, 2024
50-d avg
5.50
200-d avg
4.83
1y target
10.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 12, 2024Earnings: -0.12; estimate -0.17; surprise 29.41%
Signals (124)
NameDateAgo
MACD: Buy SignalOct 29, 20262 days ago
RSI: OversoldOct 21, 20261 week ago
RSI: OversoldOct 15, 20262 weeks ago
SMA: BearishSep 23, 20261 month ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 21, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
SMA: BullishAug 20, 20262 months ago
SMA: BullishAug 18, 20262 months ago
SMA: BearishAug 17, 20262 months ago
MACD: Buy SignalAug 14, 20262 months ago
SMA: BullishAug 13, 20262 months ago
SMA: BearishJul 24, 20263 months ago
SMA: BearishJul 23, 20263 months ago
MACD: Sell SignalJul 22, 20263 months ago
SMA: BullishJul 21, 20263 months ago
MACD: Buy SignalJul 21, 20263 months ago
SMA: BearishJul 20, 20263 months ago
MACD: Sell SignalJul 20, 20263 months ago
MACD: Buy SignalJul 15, 20263 months ago
SMA: BullishJul 14, 20263 months ago
MACD: Sell SignalJul 10, 20263 months ago
SMA: BearishJul 7, 20263 months ago
SMA: BullishJul 6, 20263 months ago
MACD: Buy SignalJun 23, 20264 months ago
MACD: Sell SignalJun 16, 20264 months ago
MACD: Buy SignalJun 12, 20264 months ago
MACD: Sell SignalJun 5, 20264 months ago
SMA: BullishMay 14, 20265 months ago
MACD: Buy SignalApr 10, 20266 months ago
RSI: OversoldMar 26, 20267 months ago
RSI: OversoldMar 20, 20267 months ago
SMA: BearishMar 13, 20267 months ago
SMA: BearishMar 12, 20267 months ago
SMA: BullishMar 10, 20267 months ago
SMA: BearishMar 2, 20268 months ago
MACD: Sell SignalMar 2, 20268 months ago
MACD: Buy SignalFeb 20, 20268 months ago
SMA: BullishFeb 17, 20268 months ago
SMA: BearishFeb 11, 20268 months ago
MACD: Sell SignalFeb 4, 20268 months ago
SMA: BullishJan 15, 20269 months ago
SMA: BearishJan 14, 20269 months ago
SMA: BullishJan 13, 20269 months ago
MACD: Buy SignalJan 13, 20269 months ago
SMA: BullishJan 12, 20269 months ago
SMA: BullishJan 7, 20269 months ago
SMA: BearishJan 5, 20269 months ago
MACD: Sell SignalDec 30, 202510 months ago
SMA: BearishDec 26, 202510 months ago
SMA: BullishDec 22, 202510 months ago
SMA: BearishDec 19, 202510 months ago
SMA: BullishDec 18, 202510 months ago
MACD: Buy SignalDec 18, 202510 months ago
MACD: Sell SignalDec 11, 202510 months ago
SMA: BearishDec 10, 202510 months ago
MACD: Buy SignalDec 8, 202510 months ago
SMA: BullishDec 4, 202511 months ago
SMA: BearishDec 1, 202511 months ago
SMA: BullishNov 25, 202511 months ago
SMA: BearishNov 19, 202511 months ago
MACD: Sell SignalNov 13, 202511 months ago
RSI: OverboughtNov 6, 202511 months ago
RSI: OverboughtNov 4, 202512 months ago
MACD: Buy SignalOct 23, 20251 year ago
SMA: BullishOct 21, 20251 year ago
SMA: BearishOct 17, 20251 year ago
MACD: Sell SignalOct 17, 20251 year ago
SMA: BullishOct 15, 20251 year ago
MACD: Buy SignalOct 15, 20251 year ago
MACD: Sell SignalOct 13, 20251 year ago
SMA: BearishOct 10, 20251 year ago
SMA: BullishOct 2, 20251 year ago
MACD: Buy SignalOct 2, 20251 year ago
MACD: Sell SignalSep 25, 20251 year ago
SMA: BearishSep 24, 20251 year ago
SMA: BullishSep 19, 20251 year ago
MACD: Buy SignalSep 18, 20251 year ago
MACD: Sell SignalSep 15, 20251 year ago
SMA: BearishSep 12, 20251 year ago
SMA: BullishSep 11, 20251 year ago
MACD: Buy SignalSep 11, 20251 year ago
SMA: BearishSep 10, 20251 year ago
SMA: BullishSep 9, 20251 year ago
SMA: BearishAug 29, 20251 year ago
MACD: Sell SignalAug 28, 20251 year ago
MACD: Buy SignalAug 27, 20251 year ago
SMA: BullishAug 22, 20251 year ago
SMA: BearishAug 15, 20251 year ago
MACD: Sell SignalAug 15, 20251 year ago
RSI: OverboughtAug 12, 20251 year ago
MACD: Buy SignalAug 11, 20251 year ago
SMA: BullishAug 5, 20251 year ago
SMA: BearishAug 1, 20251 year ago
MACD: Sell SignalAug 1, 20251 year ago
SMA: BullishJul 16, 20251 year ago
SMA: BearishJul 15, 20251 year ago
SMA: BullishJul 9, 20251 year ago
SMA: BearishJul 8, 20251 year ago
SMA: BullishJul 3, 20251 year ago
SMA: BearishJul 1, 20251 year ago
SMA: BullishJun 27, 20251 year ago
MACD: Buy SignalJun 27, 20251 year ago
SMA: BearishJun 13, 20251 year ago
SMA: BullishJun 12, 20251 year ago
SMA: BearishJun 11, 20251 year ago
MACD: Sell SignalJun 6, 20251 year ago
MACD: Buy SignalMay 27, 20251 year ago
SMA: BullishMay 15, 20251 year ago
SMA: BearishMay 14, 20251 year ago
MACD: Sell SignalMay 2, 20251 year ago
MACD: Buy SignalApr 22, 20251 year ago
MACD: Sell SignalApr 10, 20251 year ago
RSI: OverboughtApr 4, 20251 year ago
RSI: OverboughtMar 24, 20251 year ago
MACD: Buy SignalMar 19, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
RSI: OverboughtFeb 4, 20251 year ago
SMA: BullishFeb 3, 20251 year ago
MACD: Buy SignalJan 22, 20251 year ago
RSI: OversoldJan 17, 20251 year ago
RSI: OversoldJan 10, 20251 year ago
RSI: OversoldDec 26, 20241 year ago

Key statistics

Market cap
95.05M
Enterprise value
96.37M
Trailing P/E
0.00
Forward P/E
-75.83
PEG ratio
0.00
Price / sales
1.65
Price / book
8.63
EPS (TTM)
-0.92
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-31.74%
Revenue (TTM)
57.77M
Revenue growth
-57.60%
Free cash flow
-25.48M
Total cash
22.46M
Total debt
21.07M
Return on equity
-129.58%
Shares outstanding
14.89M
Short % of float
1.71%
50-day average
5.50
200-day average
4.83

Analyst view

Consensus: none

Price target (mean) 10.00 +93.4% upside
Target (low)
9.00
Target (mean)
10.00
Target (high)
11.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 12, 2024

Expected Aug 12, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
DERM Revenue — quarterly 18.51M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DERM Net income — quarterly -312.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DERM EPS — quarterly -0.01
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DERM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.17-0.12+0.05+29.41%
Aug 12, 2024Jun 1, 2024-0.15-0.17-0.02-13.33%
Aug 12, 2024Jun 1, 2024-0.15———
May 13, 2024Mar 1, 2024-0.26-0.53-0.27-103.85%
May 13, 2024Mar 1, 2024-0.26———
Mar 21, 2024Dec 1, 20230.00-0.12——

Upgrades / downgrades

DERM analyst upgrades and downgrades
DateFirmActionFromTo
Feb 16, 2024Alliance Global Partnersinit—Buy
Sep 7, 2023B. Riley SecuritiesreitBuyBuy
Jul 12, 2023B. Riley SecuritiesmainBuyBuy
May 23, 2023B. Riley SecuritiesmainBuyBuy
Mar 30, 2023B. Riley Securitiesreit—Buy
Feb 25, 2022Cantor Fitzgeraldinit—Overweight

About Journey Medical Corporation

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on DERM — it syncs with the Stock Master app.

Insider holders

DERM insider holders
InsiderRelationLatest transactionDateShares held
BENESCH JOSEPHChief Financial OfficerSaleJul 31, 202447,331
HERSKOWITZ NEILDirectorStock Award(Grant)Jul 7, 202481,445
MARAOUI CLAUDEChief Executive OfficerPurchaseMar 21, 20242,163,430
PALEY JEFFREYDirectorSaleNov 27, 202370,727
PEARCE MICHAEL COOPERDirectorStock Award(Grant)Jul 18, 202430,000
ROSENWALD LINDSAY ADirectorStock Award(Grant)Jul 7, 2024330,443

Institution ownership

DERM institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.18%325,1711.48MSep 29, 2024
Cambridge Investment Research Advisors Inc.2.11%314,4501.43MSep 29, 2024
Renaissance Technologies, LLC1.80%268,2001.22MSep 29, 2024
American Financial Group Inc.1.21%180,000819.00KSep 29, 2024
Envestnet Asset Management0.74%109,586498.62KSep 29, 2024
Geode Capital Management, LLC0.73%108,435493.38KSep 29, 2024

Fund ownership

DERM fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.42%211,446962.08KSep 29, 2024
Vanguard Extended Market Index Fund0.73%109,083496.33KSep 29, 2024
Fidelity Extended Market Index Fund0.38%57,238260.43KOct 30, 2024
World Funds Tr-Perkins Discovery Fund0.15%22,000100.10KSep 29, 2024
Fidelity Total Market Index Fund0.12%18,12482.46KOct 30, 2024
iShares Micro Cap ETF0.12%17,98581.83KOct 30, 2024
Advertisement